Short Interest in Cellectis S.A. (NASDAQ:CLLS) Expands By 59.7%

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 203,500 shares, an increase of 59.7% from the December 15th total of 127,400 shares. Based on an average daily volume of 108,400 shares, the days-to-cover ratio is currently 1.9 days.

Institutional Investors Weigh In On Cellectis

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Long Focus Capital Management LLC lifted its position in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. First Affirmative Financial Network bought a new position in Cellectis during the 3rd quarter worth approximately $45,000. Finally, XTX Topco Ltd acquired a new position in shares of Cellectis in the 2nd quarter worth approximately $29,000. Institutional investors own 63.90% of the company's stock.

Cellectis Stock Down 3.0 %

Shares of NASDAQ:CLLS traded down $0.05 during trading on Friday, hitting $1.47. The company's stock had a trading volume of 161,531 shares, compared to its average volume of 273,442. Cellectis has a fifty-two week low of $1.41 and a fifty-two week high of $3.38. The stock's 50-day moving average price is $1.84 and its two-hundred day moving average price is $2.00. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The company has a market capitalization of $81.42 million, a PE ratio of -1.13 and a beta of 3.08.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million for the quarter, compared to analysts' expectations of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter last year, the company posted ($0.31) earnings per share. As a group, sell-side analysts expect that Cellectis will post -0.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on CLLS shares. Barclays reduced their price target on shares of Cellectis from $7.00 to $5.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 5th. StockNews.com assumed coverage on shares of Cellectis in a report on Thursday. They set a "sell" rating on the stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.